bms-819881

BMS-819881 is a synthetic small molecule antagonist of the Melanin Concentrating Hormone Receptor 1 (MCHR1), developed primarily for potential anti-obesity indications. Its mechanism of action is MCHR1 antagonism, designed to modulate metabolic pathways relevant to energy homeostasis and body weight regulation. It is the active drug released from the phosphate ester prodrug BMS-830216, which was used in clinical studies to improve solubility and oral bioavailability. Studies have reported minimal hERG channel liability for BMS-819881, indicating a favorable cardiovascular safety profile in preclinical assessments. The molecule is widely used in metabolic research and therapeutic development, notably in preclinical and early-phase clinical trials for obesity[3][5][7].

Other names

(R)-6-(4-chlorophenyl)-3-(4-(2-cyclopropyl-2-hydroxyethoxy)-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one